Apollo Therapeutics is a collaborative joint venture between three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation) and the technology transfer offices of Imperial College London, University College London and the University of Cambridge.
The £40 million initiative will provide translational funding for biomedical projects developed at these universities. The aim of projects funded by Apollo is to develop promising intellectual property to the point at which it may be licensed out on commercial terms. Projects selected by Apollo will have access to the best industry-standard drug development expertise and development partners. The Apollo partners believe that this will significantly improve the speed and likelihood of university research being translated into novel medicines.
How to apply
Apollo will ultimately operate as an open-funding call, with no deadlines or application windows for researchers. Applications to Apollo from Imperial College London researchers will be managed by the Apollo Imperial Management (AIM) group for which the contacts are set-out below. You may contact any member of this group with a query and they will ensure that you receive a swift response.
If you think you have a project that you would like to be considered for funding from Apollo, please begin by emailing a member of the AIM group with an outline expression of interest. At present, please simply email some basic information on the proposition to enable a discussion and we will get back to you promptly. A more formal ‘EoI’ template form will be put in place in due course.
Who do I contact? - The Apollo-Imperial Management group (AIM) Group
Apollo is a pan-Imperial initiative involving members of the Faculty of Medicine, Faculty of Natural Sciences, Corporate Partnerships and Imperial Innovations. The names and contacts are provided below, feel free to contact any of them with questions or about a potential project proposal you would like to discuss.
Dr Vjera Magdalenic-Moussavi [FoM Corporate Partnerships] firstname.lastname@example.org
Dr Kay Penicud [FoNS Corporate Partnerships] email@example.com
Dr Sarah Wagstaffe [FoM] firstname.lastname@example.org
Dr Andrew Tingey, [Imperial Innovations] email@example.com
Dr Jon Wilkinson [Imperial Innovations] firstname.lastname@example.org
To find more information about Apollo Therapeutics you can visit their website using the link below:
Apollo has been developed to fund a wide range of biomedical projects across a number of therapeutic areas. While Apollo is focussed on therapeutics, or platform technologies which may aid the development and identification of therapeutics, there will be no therapeutic area bias, and any modality may be considered (e.g. small molecules, peptides, proteins, antibodies and gene/cell therapies). To provide some guidance, Apollo has initially identified a list of areas of interest, though it is not limited to providing funding only to these:
- Addresses unmet medical need
- Target validation: evidence relating target to disease; independent verification, on-target liability, novelty
Molecular and clinical tractability
- Screening: either phenotypic with deconvolution strategy or target/pathway identified
- Status of assays and models for project: Robustness, access to reagents, availability, throughput, translatable relevance
- Hit/lead properties (if available) activity, selectivity, physicochemical properties
Therapeutic areas of interest
These areas are not fixed, but preference will be given to applications falling within these specified areas. Please discuss your options with your local Apollo Imperial Management group representative (see contact details).
- Idiopathic pulmonary fibrosis
- Acute lung injury
- Cystic fibrosis
- Idiopathic chronic cough
- Inflammatory bowel disease
- Rheumatoid Arthritis
- Niche inflammatory diseases
- Lung cancer including EGFR signalling pathway and agents addressing resistance to SOC
- Breast cancer
- Ovarian cancer
- Urological cancers including prostate cancer, high risk or resistant patients
- GI tract – Gastric and Liver, K-Ras mutant CRC
- Haematological Cancers including AML, MM, MDS, NHL, CLL, DLBCL, Monoclonal gammopathy of undetermined significance (MGUS), in general agents addressing the B cell Receptor Signalling Pathway
- Immuno-oncology approaches, epigenetic approaches and DNA repair
METABOLIC AND CARDIOVASCULAR
- Diabetes and Diabetic complications including nephropathy
- Heart failure (systolic and diastolic) including congestive heart failure, calcium channel modulation, agents addressing mitochondrial dysfunction and novel anti fibrotic mechanisms and cardiac repair and regeneration, dyslepidemia
- Muscle building and improved function in sarcopenia and cachexia
- Anti-virals including hepatitis and respiratory viruses
- Neurodegeneration and Neuroinflammation including Alzheimers (e.g. alpha-synuclein antagonists, ApoE modulators, Gamma secretase modulators, Monoacylglycerol lipase inhibitors)
- Mood disorders including Depression and Bipolar Disorders
(e.g. Metabolic, Imunno-inflammation, CNS, Muscle Disorders, Rare Malignancies and Haematology)